End-stage renal disease in Taiwan: A case-control study

Journal of Epidemiology

Volumn 19, Issue 4, 2009, Pages 169-176

  Tsai, Su Ying ^a   Tseng, Hung Fu ^b   Tan, Hsiu Fen ^c   Chien, Yu Shu ^d   Chang, Chia Chu ^e  

^a I SHOU UNIVERSITY   (Taiwan)

^b KAISER PERMANENTE   (United States)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Case control study; End stage renal disease; Risk factors; Taiwan

Indexed keywords

HERBACEOUS AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIET SUPPLEMENTATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; RISK FACTOR; SOCIOECONOMICS; STATISTICS; TAIWAN; TRADITIONAL MEDICINE;

ADULT; CASE-CONTROL STUDIES; DEMOGRAPHY; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE STYLE; MALE; MEDICINE, TRADITIONAL; MIDDLE AGED; RISK FACTORS; SOCIOECONOMIC FACTORS; TAIWAN; YOUNG ADULT;

EID: 68549120841     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20080099     Document Type: Article

References (46)

1. Schena FP. Epidemiology of end-stage renal disease: International comparison of renal replacement therapy. Kidney Int. 2000;57 suppl 74:S39-45.
2. U.S. Renal Data System USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
3. Department of Health National Health Insurance Annual Statistical Report Taiwan, ROC, Department of Health, 2004
4. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48:727-38.
5. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis. 2004;44:185-97.
6. Ejerblad E, Fored CM, Lindblad P, Fryzek J, Dickman PW, Elinder CG, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol. 2004;15(8):2178-85.
7. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med. 1983;143(9):1687-93.
8. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol. 1990;30(5):717-23.
9. Nuyts GD, Van Vlem E, Thys J, De Leersnijder D, D'Haese PC, Elseviers MM, et al. New occupational risk factors for chronic renal failure. Lancet. 1995;346(8966):7-11.
10. Steenland NK, Thun MJ, Ferguson CW, Port FK. Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Public Health. 1990;80(2):153-7.
11. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345(25):1801-8.
12. Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16(3):791-9.
13. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156-63.
14. Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007 Jan;30(1):55-62.
15. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis. 2007;49:626-33.
16. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiology features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46-55.
17. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686-92.
18. Nortier JL, Vanherweghem JL. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology. 2002;181-182:577-80.
19. Blake C, Codd MB, Cassidy A, O'Meara YM. Physical function, employment and quality of life in end-stage renal disease. J Nephrol. 2000;13:142-9.
20. Chilcot J, Wellsted D, Da Silva-Gane M, Farrington K. Depression on Dialysis. Nephron Clin Pract. 2008;108:c256-64.
21. Hayward RA, Shapiro MF, Freeman HE, Corey CR. Inequities in health services among insured Americans. Do working-age adults have less access to medical care than the elderly? N Engl J Med. 1988;318:1507-12.
22. Blendon RJ, Aiken LH, Freeman HE, Corey CR. Access to medical care for African American and white Americans. JAMA. 1989;261:278-81.
23. Hostetter TH. Research opportunities for reducing racial disparities in kidney disease. Adv Ren Replace Ther. 2004;11:59-65.
24. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of end stage renal disease. N Engl J Med. 1982;306:1276-9.
25. Ferguson R, Grim CE, Opgenroth TJ. The epidemiology of end-stage renal disease: the six-year South-Central Los Angeles experience. 1980-1985. Am J Public Health. 1987;77:864-5.
26. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13:2363-70.
27. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med. 1995;155:1201-8.
28. Burstin HR, Lipsitz SR, Brennan TA. Socioeconomic status and risk for substandard medical care. JAMA. 1992;268:2383-7.
29. Weissman JS, Stern R, Fielding SL, Epstein AM. Delayed access to health care: risk factors, reasons, and consequences. Ann Intern Med. 1991;114:325-31.
30. Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens. 1997;15:451-6.
31. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the multiple risk factor intervention trial. JAMA. 1992;268:3085-91.
32. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-8.
33. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-94.
34. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008;51:373-84.
35. Centers for Disease Control and Prevention (CDC). Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994-2004. MMWR Morb Mortal Wkly Rep. 2007;56:253-6.
36. Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Leger CL, et al. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant. 2002;17:422-7.
37. Böhm V, Tiroke K, Schneider S, Sperschneider H, Stein G, Bitsch R. Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. Int J Vitam Nutr Res. 1997;67:262-6.
38. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Hörl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:1811-8.
39. Andreucci VE, Fissell RB, Bragg-Gresham JL, Ethier J, Greenwood R, Pauly M, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44 suppl 2:61-7.
40. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis. 2007;49:626-33.
41. Kaphle K, Wu LS, Yang NY. Herbal medicine research in Taiwan. Evid Based Complement Alternat Med. 2006;3:149-55.
42. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis. 2000;35:313-8.
43. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol. 2001;21:441-8.
44. Hong YT, Fu LS, Chung LH, Hung SC, Huang YT, Chi CS. Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr Nephrol. 2006;21:577-9.
45. Ko RJ. Perspective on the adverse reactions from traditional Chinese medicines. J Chin Med Assoc. 2004;67:109-16.
46. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37:344-50.